Mechanistically, IFNα drives cell cycle entry in HSCs with this mitogenic effect being more potent in Jak2-mutant HSCs3,8 supporting a prevailing hypothesis that molecular remissions observed in PV patients receiving IFNα are due to the preferential functional decline of the MPN stem cell pool. The gene discussed is JAK2; the disease is acquired polycythemia vera.